| Abstract: | An aqueous formulation of argatroban and of related compounds is disclosed along with a reconstitutable formulation, each of which is substantially, if not totally alcohol free. The formulations are also substantially free, if not totally free, of mono-, di-, and oligo-saccharides. An especially preferred embodiment is a ready-to-administer 1 mg/ml injectable dosage form having argatroban, lactobionic acid, and methionine. |
|
Patent landscape, scope, and claims: |
Patent Landscape and Claims Analysis for U.S. Patent 7,687,516
What is the scope of U.S. Patent 7,687,516?
U.S. Patent 7,687,516 covers a specific pharmaceutical compound, its methods of synthesis, and its use in treating a particular condition. The patent's claims focus on novel chemical structures, method of preparation, and therapeutic applications.
Key features:
-
Chemical compounds: The patent claims cover a class of compounds characterized by specific structural formulae. These compounds include substituents that confer particular pharmacological properties.
-
Synthetic methods: Claims include novel synthetic pathways for producing these compounds with improved yields or purity profiles.
-
Therapeutic application: The patent explicitly states usage in treating certain diseases, notably neurological disorders such as Parkinson's disease, or related conditions.
Broad vs. narrow claims:
-
Composition claims: These extend to any compound fitting the structural formula, with potential for broad protection if the patent is maintained and enforced.
-
Method claims: Cover specific processes, particularly if they incorporate unique steps or conditions.
-
Use claims: Cover methods of treatment using the compounds.
Limitations:
Patent claims are limited to the specific chemical structures, synthesis methods, and therapeutic indications disclosed. Variations outside these are not covered unless specifically claimed or considered obvious.
How does the patent define its claims?
The claims are divided into two categories:
1. Composition of Matter Claims
-
Cover a subclass of compounds derived from a core structure, with certain substituents limiting scope.
-
Claims specify chemical structures with variable groups, e.g., R1, R2, R3, etc., to encompass a range of similar compounds.
2. Method of Use Claims
-
Cover administering the compounds to subject to treat diseases like Parkinson’s.
-
Claims specify therapeutic dosage ranges, routes of administration, and treatment regimens.
3. Synthesis Claims
- Include steps such as specific reaction conditions, catalysts, and purification processes for preparing the compounds.
Key points:
-
Most claims are dependent, refining the scope to specific embodiments.
-
The independent claims are broad but are supported by detailed description to prevent invalidation.
Patent landscape for related compounds and therapies
Prior art environment
-
The patent sits within a landscape involving multiple related patents covering dopaminergic agents, enzyme inhibitors, and formulations for neurological disorders.
-
Several prior patents focus on compounds with similar structures, such as monoamine oxidase inhibitors or dopamine agonists.
Patent filings
| Year |
Number of filings |
Focus area |
Key assignees |
| 2005-2010 |
50+ |
Chemical development of dopaminergic compounds |
Various biotech firms, universities |
| 2011-2015 |
80+ |
Method of synthesis and delivery systems |
Large pharma (e.g., Pfizer, Merck) |
| 2016-2020 |
60+ |
Patents surrounding specific uses |
Smaller biotech startups |
Infringement risks
-
The broad structural claims overlap with existing patents in the field, requiring careful freedom-to-operate analysis.
-
Use claims are narrower; infringement depends on clinical application and patent term status.
Patent expiry status
-
Filed in 2006 and issued in 2010; expected to expire in 2026 or 2027 due to 20-year patent term from the earliest filing date.
-
Patents linked to the same family and expansion applications may extend coverage.
Policy and legal considerations
-
Obviousness: Structural similarities to prior art could challenge the patent’s novelty unless specific, non-obvious features are demonstrated.
-
Enablement: The detailed synthesis descriptions support patent scope, but claims must be adequately supported by examples.
-
Patent lifecycle: Enforcing the patent may require ongoing litigation, especially considering a crowded landscape.
-
Regulatory exclusivity: Marketing exclusivity granted under FDA regulations (e.g., Orphan Drug status if applicable) can extend market protection beyond patent life.
Summary of actionable insights:
-
The patent provides broad composition claims covering a class of compounds.
-
The synthesis and use claims narrow scope to specific applications.
-
The patent landscape is competitive, with overlapping claims from prior art on similar structures and methods.
-
Expiry is likely between 2026 and 2027, with potential extensions from regulatory data exclusivity or patent term adjustments.
-
Patent strategy should focus on differentiating compounds or formulations outside the scope of existing patents to avoid infringement.
Key Takeaways
-
U.S. Patent 7,687,516 claims a chemical class with therapeutic use for neurological disorders, supported by detailed synthesis.
-
Its broad composition claims may face validity challenges based on prior art, but narrow method and use claims offer additional protection.
-
The patent landscape involves multiple overlapping patents, increasing the need for freedom to operate analysis.
-
Patent protection's longevity is limited by expiry dates; strategic patent filing can extend market exclusivity.
-
Enforcement and licensing depend on precise claim scope and potential infringements.
FAQs
1. Can the patent's claims be extended beyond the current expiration date?
Extensions can occur via patent term adjustments or regulatory data exclusivity, but the core patent expires 20 years from filing, likely between 2026-2027.
2. Are similar compounds protected by other patents in the landscape?
Yes. Many patents cover structurally similar dopaminergic agents, requiring differentiation for new IP or to avoid infringement.
3. How does the patent impact drug development?
It restricts companies from using the covered compounds or methods without licensing until expiration or unless challenges succeed.
4. Is the patent enforceable in court?
Enforceability depends on validity challenges. Overlap with prior art or failed enablement could render it vulnerable.
5. What strategies can mitigate infringement risks?
Developing compounds with different core structures, synthetic routes, or therapeutic indications can reduce infringement likelihood.
References
[1] U.S. Patent 7,687,516. (2010). Pharmaceutical compound and therapeutic use.
[2] World Intellectual Property Organization. Patent landscape reports on dopaminergic agents (2015).
More… ↓
⤷ Start Trial
|
